Another Win for Novel Drug, This Time in EGFR-Mutated Lung Cancer

A phase III trial conducted in China has shown promising results for izalontamab brengitecan (iza-bren), a first-in-class bispecific antibody-drug conjugate, in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who had progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs). The trial, known as PANKU-Lung01, demonstrated that izabren nearly doubled progression-free survival (PFS) compared to chemotherapy, with a median PFS of 11.1 months versus 5.7 months.

The benefit was observed across all prespecified subgroups, and confirmed objective responses were seen in 60.2% of patients receiving izabren versus 34.5% of those receiving chemotherapy. While overall survival data were still immature, the interim estimate favored izabren. The results suggest that izabren could be a promising new treatment option for EGFR-mutant NSCLC patients with EGFR TKI resistance, supporting its potential as a novel therapy in this patient population.

Brief written by urgent.news from MedPage Today's own syndicated text. Machine-written — may contain errors; check the original before relying on it.